Today we announced the sale of our ALZET product line to Lafayette Instrument Co. Learn more in the press release here: https://bit.ly/3ANTYhA
关于我们
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR? (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER? platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
- 网站
-
https://www.durect.com
DURECT Corporation的外部链接
- 所属行业
- 制药业
- 规模
- 51-200 人
- 类型
- 上市公司
- 创立
- 1998
DURECT Corporation员工
动态
-
In case you missed it, this recent Xtalks interview, featuring our CEO, Dr. Jim Brown, highlights the impact our #epigenetic candidate has on treating patients with alcohol-associated #hepatitis (#AH). Watch here for more on our therapeutic approach: https://bit.ly/3Y0xam2
-
-
We reported our financial results today and provided a corporate update for the third quarter 2024. For more information and to access the webcast replay, visit: https://bit.ly/4ewWGFT
-
-
Save the date for our third quarter 2024 financial results and corporate update conference call on November 13th. For more information and to access the live webcast, visit: https://bit.ly/4ffIhim
-
-
Alcohol-associated #hepatitis (#AH) can affect both women and men and more than half of the people diagnosed are between 40 and 60 years old. Listen to patient advocate Jay’s story with the American Liver Foundation to learn more about his experience with AH: https://bit.ly/3BhM5AR
-
Our CMO, Norman Sussman, M.D., shares insights on his experience in treating alcohol-associated #Hepatitis and the need for therapies that can improve patient outcomes. Learn more about our work here: https://bit.ly/3U2xsbc #LiverAwarenessMonth
-
-
Did you know, alcohol-associated #hepatitis (#AH) causes more than ~164,000 hospitalizations per year? With the rate of #AH rising, there is an unmet need for novel therapeutic strategies to improve survival rates. At DURECT, we’re leading therapeutic innovation. Learn more here: https://bit.ly/3X52KAj #LiverAwarenessMonth
-
-
We are pleased to announce that we will be delivering an oral and two poster presentations on larsucosterol and alcohol-associated hepatitis (#AH) at the 2024 Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD) in San Diego! Learn more here: https://bit.ly/3BI9cVe #AASLD
-
-
Our CEO, Dr. Jim Brown, had the pleasure of joining Ayesha Rashid in the recent Xtalks episode. Tune in to hear how we are leveraging the potential of #EpigeneticModulation to alter the trajectory of severe and life-threatening conditions, like alcohol-associated hepatitis (#AH), and plans to advance a Phase 3 trial in AH. Watch here: https://bit.ly/3Y0xam2
Modulating the Code: The Promise of Epigenetic Therapeutics in Alcohol-Associated Hepatitis ft. DURECT President and CEO Dr. James Brown
xtalks.com
-
This #LiverAwarenessMonth, we are highlighting the challenges faced by patients affected by liver disease and the importance of early detection through symptom awareness. At DURECT, we are committed to developing treatments supporting liver health, with a special focus on addressing alcohol-associated #Hepatitis (#AH) and the impact of alcohol on liver function. Learn more about AH and our therapeutic approach: https://bit.ly/3X52KAj
-